TABLE 1.
Comparison of baseline clinical characteristics between the two titer groups in overall cohort, CTX group, and TAC group.
| Parameters | Overall cohort | CTX group | TAC group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | High titer | Non-high titer | p-value | Total | High-titer | Non-high titer | p-value | Total | High titer | Non-high titer | p-value | |
| (n = 447) | (n = 131) | (n = 316) | (n = 275) | (n = 71) | (n = 204) | (n = 172) | (n = 60) | (n = 112) | ||||
| Age (years) | 54 (44, 64) | 55 (47, 63) | 53 (42, 64) | 0.124 | 53 (44, 63) | 54 (47, 61) | 53 (43, 64) | 0.394 | 54 (43, 64) | 56 (47, 65) | 53 (37, 64) | 0.187 |
| Male gender (%) | 317 (70.92) | 95 (72.52) | 222 (70.25) | 0.631 | 198 (72.00) | 51 (71.83) | 147 (72.06) | 0.971 | 119 (69.19) | 44 (73.33) | 75 (66.96) | 0.389 |
| SBP (mmHg) | 129 (120, 139) | 130 (122, 139) | 129 (120, 140) | 0.191 | 128 (120, 138) | 129 (121, 137) | 128 (118, 139) | 0.379 | 130 (120, 140) | 132 (122, 140) | 130 (120, 141) | 0.432 |
| DBP (mmHg) | 80 (74, 89) | 83 (75, 88) | 80 (73, 89) | 0.079 | 80 (73, 88) | 83 (75, 87) | 80 (72, 88) | 0.102 | 82 (74, 90) | 83 (72, 92) | 81 (74, 90) | 0.428 |
| Serum creatinine (µmol/L) | 77.89 (63.49, 96.49) | 82.20 (64.50, 99.13) | 77.44 (63.33, 93.54) | 0.186 | 78.00 (64.10, 97.00) | 79.00 (62.63, 98.17) | 77.95 (64.34, 94.85) | 0.872 | 77.47 (62.34, 94.95) | 85.08 (65.42, 101.63) | 75.41 (61.49, 90.95) | 0.057 |
| Serum albumin (g/L) | 24.87 (20.67, 28.18) | 20.62 (18.20, 22.38) | 27.10 (23.10, 28.59) | <0.001 | 25.61 (20.70, 28.30) | 20.57 (18.14, 22.80) | 26.87 (23.10, 28.51) | <0.001 | 23.37 (20.42, 28.13) | 20.74 (18.43, 22.17) | 27.25 (22.99, 28.84) | <0.001 |
| eGFR (ml/min/1.73 m2) | 93.02 (74.83, 106.83)< | 88.93 (75.22, 103.46) | 95.41 (73.72, 107.86) | 0.067 | 92.18 (73.26, 106.92) | 89.65 (75.90, 105.05) | 94.64 (72.87, 107.18) | 0.404 | 94.27 (75.45, 106.64) | 88.90 (69.42, 102.44) | 96.32 (76.52, 109.91) | 0.070 |
| Urinary protein (g/24 h) | 7.02 (4.60, 10.37) | 11.18 (9.51, 13.66) | 5.62 (4.33, 7.78) | <0.001 | 6.80 (4.55, 10.07) | 10.53 (9.12, 14.38) | 5.78 (4.30, 7.59) | <0.001 | 7.90 (4.78, 11.44) | 11.69 (10.10, 13.32) | 5.51 (4.37, 7.92) | <0.001 |
| TG (mmol/L) | 2.37 (1.67, 3.38) | 2.48 (1.75, 3.65) | 2.33 (1.64, 3.36) | 0.271 | 2.38 (1.64, 3.39) | 2.17 (1.59, 3.58) | 2.39 (1.64, 3.38) | 0.902 | 2.36 (1.72, 3.37) | 2.53 (1.89, 3.86) | 2.23 (1.65, 3.25) | 0.064 |
| TCHO (mmol/L) | 8.20 (6.81, 9.82) | 8.51 (7.22, 10.11) | 8.03 (6.65, 9.67) | 0.081 | 8.14 (6.83, 9.82) | 8.42 (6.91, 10.11) | 8.03 (6.80, 9.67) | 0.502 | 8.21 (6.67, 9.81) | 8.78 (7.56, 10.15) | 7.97 (6.43, 9.64) | 0.065 |
| HDL-chol (mmol/L) | 1.50 (1.13, 2.01) | 1.45 (1.05, 1.98) | 1.51 (1.16, 2.05) | 0.161 | 1.59 (1.12, 2.13) | 1.55 (1.02, 2.05) | 1.60 (1.14, 2.16) | 0.323 | 1.40 (1.14, 1.88) | 1.34 (1.07, 1.87) | 1.48 (1.16, 1.88) | 0.384 |
| LDL-chol (mmol/L) | 4.73 (3.58, 5.95) | 4.99 (3.91, 6.14) | 4.61 (3.50, 5.90) | 0.063 | 4.71 (3.58, 6.12) | 4.84 (3.73, 6.35) | 4.61 (3.58, 5.90) | 0.378 | 4.77 (3.58, 5.91) | 5.03 (4.25, 6.06) | 4.61 (3.14, 5.91) | 0.092 |
| PLA2R titer (RU/ml) | 87.59 (39.48, 200.00) | 280.61 (226.79, 360.18) | 59.02 (31.83, 95.10) | <0.001 | 80.70 (37.33, 160.50) | 280.61 (215.70, 356.63) | 61.35 (32.00, 99.92) | <0.001 | 94.60 (42.67, 240.58) | 281.44 (231.87, 370.74) | 52.1 (30.15, 92.18) | <0.001 |
Data were shown as median (25–75% interquartile range). p-value: high titer vs. non-high titer. p-value <0.05 was considered statistically significant. CTX, cyclophosphamide; TAC, tacrolimus; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; TG, triglyceride; TCHO, total cholesterol; HDL-chol, high-density lipoprotein cholesterol; LDL-chol, low-density lipoprotein cholesterol; PLA2Rab, antibodies against the M-type phospholipase-A2-receptor